US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SKHY $195.02 ▲+0.00% SNDK $1,704.16 ▲+0.00% TSLA $378.73 ▲+0.00% SDEV $3.94 ▲+0.00% INTC $116.19 ▲+0.00%
FinancialContent

Satellos Bioscience Inc. - Common Stock (NQ:MSLE)

8.050 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Satellos Bioscience Inc. - Common Stock

News headline image
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update ↗
Satellos Bioscience (NASDAQ:MSLE) said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne... 
Via MarketBeat
News headline image
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in Upcoming Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours ↗
SAT-3247, an oral therapy aimed at restoring muscle repair, is now in Phase 2 testing in children with DMD. 
Via Stocktwits
News headline image
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
From Satellos Bioscience Inc.
Via Business Wire